FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B‐Cell Acute Lymphoblastic Leukemia

On July 11, 2017, the Food and Drug Administration granted approval for blinatumomab for the treatment of relapsed or refractory (R/R) precursor B‐cell acute lymphoblastic leukemia (ALL). Blinatumomab is a bispecific CD19‐directed CD3 T‐cell engager. The basis for the approval included results from...

Descripción completa

Detalles Bibliográficos
Autores principales: Pulte, E. Dianne, Vallejo, Jonathon, Przepiorka, Donna, Nie, Lei, Farrell, Ann T., Goldberg, Kirsten B., McKee, Amy E., Pazdur, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Regulatory Issues: FDA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291336/
https://www.ncbi.nlm.nih.gov/pubmed/30018129
http://dx.doi.org/10.1634/theoncologist.2018-0179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291336/
https://www.ncbi.nlm.nih.gov/pubmed/30018129
http://dx.doi.org/10.1634/theoncologist.2018-0179

Ejemplares similares